Form 4: NeuroOne CEO Disposes Shares for Tax Obligation

NeuroOne Medical Technologies Corp. CEO David A. Rosa reported a disposal of 2,458 common shares on September 30, 2025, to satisfy tax liabilities.

Summary

• David A. Rosa, CEO and President, Director, and 10% Owner of NEUROONE MEDICAL TECHNOLOGIES Corp (NMTC), reported a transaction.
• On September 30, 2025, Mr. Rosa disposed of 2,458 shares of common stock.
• The disposal was executed at a price of $0.8886 per share.
• Following this transaction, Mr. Rosa beneficially owns 1,156,373 shares of common stock directly.
• The transaction code 'F' indicates that the shares were disposed of to cover tax liability by withholding securities.

Sentiment

Score: 5

Explanation: The transaction is a routine tax-related disposal of a small portion of holdings, which is neutral in terms of company performance or insider sentiment.

Future Outlook

NA

Industry Context

This is a routine insider transaction report (Form 4) and does not provide information relevant to broader industry trends or the competitive landscape for NeuroOne Medical Technologies Corp.

Stakeholder Impact

• Minimal impact on shareholders as this is a routine, non-discretionary transaction for tax purposes and represents a small fraction of the CEO's total holdings.

Key Dates

Recommendation

This Form 4 filing details a routine, non-discretionary disposal of shares by the CEO to cover tax liabilities. It does not reflect a change in management's outlook on the company's prospects or a significant reduction in their overall stake, thus it has no material impact on the investment thesis for NeuroOne Medical Technologies Corp. and does not warrant a change in investment recommendation.

Keywords

NeuroOne Medical Technologies, NMTC, David A. Rosa, Insider Transaction, Form 4, Stock Disposal, CEO, Tax Withholding